In March 2011, investigators from Australia and several other countries published the results of the DECRA trial in the New England Journal of Medicine. This was a randomized trial comparing decompressive craniectomy to best medical therapy run between 2002 and 2010 to assess the optimal management of patients with medically refractory ICP following diffuse non-penetrating head injury. The study investigators found that decompressive craniectomy was associated with worse functional outcomes, as measured by a standard metric, than best medical care. There were no differences in deaths between groups 1).
Cattle encephalon glycoside and ignotin injection (drug approval H22025046; Jilin Sihuan Pharmaceutical Co. LTD., Jilin, People’s Republic of China) was approved by the Chinese Food and Drug Administration in 2011.